Name: 阿斯利康發現疫苗不會增加血栓風險 (AstraZeneca finds no increased blood clot risk from vaccine)
Uploaded: 2021-03-15T20:10:33.000Z
Duration: 1 min 22 s

AstraZeneca said Sunday a review of safety data showed there was no evidence it's vaccine raises the risk of blood clots.

阿斯利康週日表示，安全數據的審查顯示，沒有證據表明它的疫苗會提高血栓的風險。

The company's review covered more than 17 million people vaccinated in the United Kingdom and European Union, and comes amid a flurry of suspensions over alleged clotting issues.

該公司的審查覆蓋了英國和歐盟1700多萬人的疫苗接種，而且是在因涉嫌凝血問題而紛紛停產的情況下進行的。

Authorities in a number of countries, including Ireland, Austria and the Netherlands, have suspended the vaccine.

包括愛爾蘭、奧地利和荷蘭在內的一些國家的當局已經暫停了疫苗。

In a statement, the company said AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombosis subpoena in any defined age group, gender batch or in any particular country, the drugmaker added 37 blood related incidents have been reported so far, which it says is similar across other licensed covid 19 vaccines.

在一份聲明中，該公司表示，阿斯利康沒有顯示出任何證據表明在任何確定的年齡組，性別批次或在任何特定的國家，肺栓塞，深靜脈血栓或血栓傳票的風險增加，該製藥商補充說，到目前為止，已經有37起血液相關事件的報告，它說，在其他許可的covid 19疫苗中，這是類似的。

The company plans to publish the monthly safety report on the European Medicines Agency website within the next week.

該公司計劃在下週內在歐洲藥品管理局網站上公佈月度安全報告。

 AstraZeneca's vaccine, developed with Oxford University, has been authorized for use in the European Union and other countries, but not yet in the United States. 

阿斯利康與牛津大學合作開發的疫苗已獲准在歐盟和其他國家使用，但尚未在美國使用。